IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial February 23, 2026 Read More »
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout April 14, 2026 Read More »
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts April 8, 2026 Read More »
